Daniel Betticher

Overview

Explore the profile of Daniel Betticher including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 38

Citations 485

Followers 0

Related Specialties

Oncology

General Medicine

General Surgery

Top 10 Co-Authors

Thomas Pabst

Miklos Pless

Solange Peters

Behrouz Mansouri Taleghani

Urban Novak

Thomas Egger

Daniel Rauch

Barbara Jeker

Thilo Zander

Karin Ribi

Published In

Lung Cancer

Bone Marrow Transplant

Rev Med Suisse

Swiss Med Wkly

J Thorac Oncol

Affiliations

Soon will be listed here.

Recent Articles

11.

[Immunotherapy: also in elderly patients ?]

Rhyner Agocs G, Dougoud-Chauvin V, Betticher D

Rev Med Suisse . 2019 Sep; 15(660):1512-1515. PMID: 31496176

The emergence of immunotherapy has generated great enthusiasm in oncology improving the prognosis of pathologies such as melanoma, lung cancer, kidney cancer, bladder and head and neck cancers. This enthusiasm...

12.

Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?

Moser S, Bacher U, Jeker B, Taleghani B, Betticher D, Ruefer A, et al.

Hematol Oncol . 2019 Sep; 37(5):649-651. PMID: 31483507

No abstract available.

13.

Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study

Rothschild S, Betticher D, Zenhausern R, Anchisi S, Von Moos R, Pless M, et al.

Cancer Chemother Pharmacol . 2019 Aug; 84(4):881-889. PMID: 31444619

Purpose: The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer...

14.

Swiss Delphi study on iron deficiency

Nowak A, Angelillo-Scherrer A, Betticher D, Dickenmann M, Guessous I, Juillerat P, et al.

Swiss Med Wkly . 2019 Jul; 149:w20097. PMID: 31269223

Aims Of The Study: Iron deficiency (ID) and iron deficiency anaemia (IDA) are important conditions affecting a large proportion of the general population, causing the patients physical and psychosomatic symptoms,...

15.

Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg

Peisl S, Zimmermann S, Camey B, Betticher D, Bouchardy C

BMC Cancer . 2019 May; 19(1):469. PMID: 31101028

Background: Breast cancer screening mammography is widespread in industrialised countries within the framework of public health program or opportunist form. Only few data exist on the comparison of effectiveness between...

16.

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

Curioni-Fontecedro A, Perentes J, Gelpke H, Xyrafas A, Bouchaab H, Mach N, et al.

Br J Cancer . 2019 Apr; 120(10):968-974. PMID: 30988393

Background: Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate...

17.

High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients

Prediletto I, Farag S, Bacher U, Jeker B, Taleghani B, Bregy R, et al.

Bone Marrow Transplant . 2019 Mar; 54(12):1923-1925. PMID: 30890768

No abstract available.

18.

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma

Amsler I, Jeker B, Taleghani B, Bacher U, Betticher D, Egger T, et al.

Leuk Lymphoma . 2019 Jan; 60(2):511-514. PMID: 30616438

No abstract available.

19.

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma